Atara Biotherapeutics, Inc (ATRA) insider trading

Every open-market stock purchase and sale by Atara Biotherapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Insiders bought $4.7M over the last 12 months (1 buy).
  • Insiders sold $3.8M over the last 12 months (8 sales).
  • Last insider buy: EcoR1 Capital LLC (10% owner), $4.7M, 5 months ago.

Last 12 months: insiders bought $4.7M (1 buy) and sold $3.8M (8 sales). Last close $9.92 on Jun 4, 2026.

Recent ATRA insider trades

DateInsiderTradeValue
Jun 11, 2026Brian N Cherry (Insider)Bought (not open market)—
Jun 9, 2026Matthew K Fust (Insider)Bought (not open market)—
Jun 9, 2026William K Heiden (Insider)Bought (not open market)—
Jun 9, 2026Gregory Austin Ciongoli (Insider)Bought (not open market)—
May 18, 2026AnhCo Nguyen (CEO)Sold$47.8K
May 18, 2026Yanina Grant-Huerta (C-suite exec)Sold$22K
May 7, 2026EcoR1 Capital LLC (10% owner)Bought$4.7M
May 7, 2026Panacea Innovation Ltd (Insider)Sold$3.2M
Mar 17, 2026Panacea Innovation Ltd (Insider)Bought (not open market)$1.7M
Mar 17, 2026Panacea Innovation Ltd (Insider)Sold (not open market)$26
Mar 9, 2026Yanina Grant-Huerta (C-suite exec)Bought (not open market)—
Mar 9, 2026AnhCo Nguyen (CEO)Bought (not open market)—
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$8.1K
Mar 2, 2026AnhCo Nguyen (CEO)Sold$7.3K
Mar 2, 2026AnhCo Nguyen (CEO)Sold$6.6K
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$1.9K
Mar 2, 2026AnhCo Nguyen (CEO)Sold$1K
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$508
Mar 2, 2026AnhCo Nguyen (CEO)Sold$295
Mar 2, 2026Yanina Grant-Huerta (C-suite exec)Sold$122
Jan 12, 2026Panacea Innovation Ltd (Insider)Sold$489K
Nov 28, 2025Panacea Innovation Ltd (Insider)Bought (not open market)$322K
Nov 28, 2025Panacea Innovation Ltd (Insider)Sold (not open market)$14
Nov 17, 2025AnhCo Nguyen (CEO)Sold$37.7K
Nov 17, 2025Yanina Grant-Huerta (C-suite exec)Sold$21.7K

Who's trading ATRA

Get free alerts when an insider at Atara Biotherapeutics, Inc files a new trade →